ANIP
NASDAQANI Pharmaceuticals Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
Price$81.05+4.52 (+5.90%)
2026-03-042026-06-05
News · 26 weeks72-82%
2025-12-142026-06-07
Mix2990d
- Insider14(48%)
- SEC Filings7(24%)
- Other6(21%)
- Earnings2(7%)
Latest news
25 items- PRANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare ConferencePRINCETON, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) (ANI or the Company) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference as follows: Date:Wednesday, June 3, 2026 Time:3:45 p.m. ET Webcast:Click Here The live and archived webcast will be accessible from the Company's website at www.anipharmaceuticals.com, under the Investors section under Events and Presentations. The replay of the webcast will be accessible for 90 days. About ANI ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) is a diversified biopharmaceutical company committed to its mission of "Serving Pa
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- INSIDERDirector Walsh Patrick D sold $1,127,120 worth of shares (13,973 units at $80.66), decreasing direct ownership by 27% to 38,432 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew sold $36,357 worth of shares (459 units at $79.21), decreasing direct ownership by 1% to 38,271 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERPRESIDENT & CEO Lalwani Nikhil sold $4,266,350 worth of shares (55,000 units at $77.57), decreasing direct ownership by 14% to 349,889 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, GENERICS Gutwerg Ori sold $220,374 worth of shares (2,772 units at $79.50), decreasing direct ownership by 3% to 78,696 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $39,080 worth of shares (500 units at $78.16) as part of a pre-agreed trading plan, decreasing direct ownership by 0.63% to 78,390 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- SECSEC Form 10-Q filed by ANI Pharmaceuticals Inc.10-Q - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial GuidanceQuarterly net revenues of $237.5 million, an increase of 20.5% year-over-yearPurified Cortrophin® Gel net revenues of $75.1 million, an increase of 42.1% year-over-yearQuarterly GAAP net income available to common shareholders of $29.5 million; Quarterly adjusted non-GAAP EBITDA of $63.0 million, an increase of 24.1% year-over-yearDiluted GAAP income per share of $1.28 and adjusted non-GAAP diluted earnings per share of $2.05Raised 2026 total net revenue guidance to $1,080 million to $1,140 million, adjusted non-GAAP EBITDA to $285 million to $300 million, and adjusted non-GAAP diluted earnings per share to $9.19 to $9.69; reaffirmed 2026 Cortrophin Gel net revenue guidance of $540 million t
- PRANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ETPRINCETON, N.J., April 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that the Company will release its first quarter 2026 financial results on Friday, May 8, 2026, prior to the market open. Nikhil Lalwani, President and Chief Executive Officer, Stephen P. Carey, Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz, Head of Rare Disease will host a webcast and conference call to discuss the results. To view the webcast, please click here. Links to access the webcast and conference call will also be available on the "Events & Presentations" page of the Company's website at https://www.anipharmaceuticals.com,
- PRANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT ExclusivityPRINCETON, N.J., April 20, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Pimozide Tablets 1 mg and 2 mg. ANI's Pimozide Tablets is the generic version of the reference listed drug (RLD) Orap®. "We are proud to announce the launch of Pimozide Tablets with 180-Day CGT exclusivity. We are excited to bring limited competition products to market and continue to provide generic alternatives to our customers and patients," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. U.S. annual sales for Pimozide Tablets total approximately $3.1 million, based on February 2026 moving annual total (MAT) IQVIA data. A
- INSIDERSEC Form 4 filed by Cook Meredith4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- PRANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release CapsulesPRINCETON, N.J., April 13, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced the launch of Carbamazepine Extended-Release Capsules, 100 mg, 200 mg and 300 mg. ANI's Carbamazepine Extended-Release Capsules are the generic version of the reference listed drug (RLD) Carbatrol®. "Continuing to strengthen our Generics portfolio through strategic product launches remains a key priority for us," stated Nikhil Lalwani, President and Chief Executive Officer of ANI. "The launch of Carbamazepine Extended-Release Capsules, another limited competition product, highlights our continued commitment to improving patient access to essential medicines whil
- SECSEC Form DEFA14A filed by ANI Pharmaceuticals Inc.DEFA14A - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- SECSEC Form DEF 14A filed by ANI Pharmaceuticals Inc.DEF 14A - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate TabletPRINCETON, N.J., April 08, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that following final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA), the Company launched Isosorbide Mononitrate Tablet USP, 10 mg and 20 mg. ANI's Isosorbide Mononitrate Tablet USP is the generic version of the reference listed drug (RLD) Monoket®. "We are pleased to announce FDA approval and launch of Isosorbide Mononitrate Tablet USP, which highlights our efforts to bring limited-competition products to market and ensure that our high-quality products are readily accessible to our customers and patien
- SECANI Pharmaceuticals Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits8-K - ANI PHARMACEUTICALS INC (0001023024) (Filer)
- PRANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in OphthalmologyPRINCETON, N.J., April 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced publication of the results from the NEW DAY clinical trial involving ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in appropriate patients with diabetic macular edema in Ophthalmology, the journal of the American Academy of Ophthalmology. The company previously announced results from the NEW DAY trial in July 2025. ILUVIEN is a corticosteroid indicated for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in
- SECAmendment: SEC Form SCHEDULE 13G/A filed by ANI Pharmaceuticals Inc.SCHEDULE 13G/A - ANI PHARMACEUTICALS INC (0001023024) (Subject)
- INSIDERHEAD OF RARE DISEASE Mutz Christopher sold $226,526 worth of shares (3,162 units at $71.64), decreasing direct ownership by 3% to 91,309 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSVP, HEAD - ESTABLISHED BRANDS Rowland Thomas Andrew sold $357,471 worth of shares (4,772 units at $74.91), decreasing direct ownership by 11% to 38,730 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERSR. VP, GENERAL COUNSEL & SEC. Cook Meredith sold $36,310 worth of shares (500 units at $72.62), decreasing direct ownership by 0.63% to 79,390 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
- INSIDERHEAD OF RARE DISEASE Mutz Christopher sold $424,617 worth of shares (5,723 units at $74.19) and covered exercise/tax liability with 3,314 shares, decreasing direct ownership by 9% to 94,471 units (SEC Form 4)4 - ANI PHARMACEUTICALS INC (0001023024) (Issuer)
ANIP FAQ
6 questionsWhat does ANI Pharmaceuticals Inc. do?
ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; and potent products, as well as performs contract manufacturing for other pharmaceutical companies. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, and group...Where does ANIP stock trade?
ANI Pharmaceuticals Inc. (ANIP) is listed on NASDAQ.What sector and industry is ANIP in?
ANI Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about ANIP?
ANI Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Buy on 2025-07-10.What companies are similar to ANIP?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare ANIP side-by-side with any of them on Quantisnow.How can I track ANIP on Quantisnow?
Quantisnow aggregates ANI Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ANIP to receive live email and push alerts on every new disclosure.